XENE (Xenon Pharmaceuticals) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Xenon Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2024 was $-55.17 Mil. Xenon Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Xenon Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Xenon Pharmaceuticals's current FCF Yield % is -7.67%.

The historical rank and industry rank for Xenon Pharmaceuticals's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Xenon Pharmaceuticals was -87.19%. The lowest was -9337.94%. And the median was -388.09%.

XENE's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -126.31
* Ranked among companies with meaningful FCF Margin % only.

Xenon Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Xenon Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals FCF Margin % Chart

Xenon Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-157.81

-388.09

-1,101.57

Xenon Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Xenon Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Xenon Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Xenon Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Xenon Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-184.464	/	0
	=	%

Xenon Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-55.168	/	0
	=	%

Xenon Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

XP0:Germany

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Executives

Ian Mortimer	director, officer: PRESIDENT & CEO	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Sherry Aulin	officer: Chief Financial Officer	200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Gary Patou	director
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Sherrington Robin	officer: SVP Bus. & Corp. Development	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover	director	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Simon N. Pimstone	director	200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney	officer: Chief Medical Officer	200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio	officer: Chief Legal Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
James R. Empfield	officer: SVP, Drug Discovery	200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von	officer: Chief Commercial Officer	200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W